Ranolazine: a new option in the management of chronic stable angina (Q37015957)

17 August 2017

1 reference

title

Ranolazine: a new option in the management of chronic stable angina (English)

1 reference

17 August 2017

Paul P Dobesh

1

1 reference

17 August 2017

Toby C Trujillo

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

27

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1659-1676

1 reference

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Cellular mechanisms of myocardial stunning

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Elevation in cytosolic free calcium concentration early in myocardial ischemia in perfused rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Intracellular Na+ regulation in cardiac myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Value of exercise treadmill testing in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Clinical relevance and management of drug-related QT interval prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Assessing predictors of drug-induced torsade de pointes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Serial exercise testing in patients with effort angina: variable tolerance, fixed threshold

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Duration of effects of isradipine during twice daily therapy in angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Effects of 8:00 A.M. and 2:00 P.M. Doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

Inhibition of late (sustained/ persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1659

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.12.1659

1 reference

17 August 2017

1 reference